Picture Berlin Partner German Biotech Days 2024 in Berlin 650x100px
Document › Details

Iontas Ltd.. (6/5/18). "Press Release: Iontas Signs Collaboration Agreement with LG Chem, Ltd. to Identify Therapeutic Oncology Leads". Cambridge & Seoul.

Organisation Organisation Iontas Ltd.
  Group FairJourney Biologics (FJB) (Group)
Products Product antibody cancer drug
  Product 2 drug discovery services
Persons Person Butt, Neil (Orbit Discovery 202106– CEO before Iontas + Abzena + Antitope)
  Person 2 Cuddon, Lorna (Zyme Communications 201007– Managing Director + Founder before College Hill Life Sciences)

IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has signed a collaboration agreement with Korean-based LG Chem, Ltd. for the discovery of therapeutic antibodies targeting undisclosed targets for use in the treatment of cancers. Under the agreement IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by LG Chem, Ltd. and to further prove the biological activity of the antibodies.

Dr Neil Butt, CBO of IONTAS, said: “This new agreement marks IONTAS’ expansion into the Asian market, and we are delighted to have been selected by LG Chem, Ltd., after a rigorous diligence process. The application of our proprietary technologies will assist LG Chem, Ltd. in expanding its current therapeutic pipeline by generating leads against pre-defined specifications agreed at the project outset.”

Dr Myung Jin Kim, Executive Vice President / R&D Leader, Life Sciences R&D of LG Chem, Ltd., said: “IONTAS was selected because of its robust track record and technical know-how. We feel confident this collaboration will result in a strong panel of therapeutic leads which will help develop our oncology pipeline.”

Dr Neil Butt and Dr Mike Dyson, CTO of IONTAS, will attend the 2018 BIO International Convention (Boston, MA) from June 4 – 7 and Dr John McCafferty, CEO and Founder of IONTAS, will be at Antibody Engineering and Therapeutics Europe (Amsterdam, NL) from 5 – 7 June.

For further information, please visit


Notes to Editors

Image: Dr Neil Butt, Chief Business Officer of IONTAS
For a high-resolution image please contact


Neil Butt, Chief Business Officer
Tel: +44 1223 750801

Zyme Communications

Lorna Cuddon
Tel: +44 (0)1223 968 920

To opt-out from receiving press releases from Zyme Communications please email To view our privacy policy please click here.


IONTAS is a biotechnology company focused on antibody discovery and cutting-edge technology development. IONTAS offers services for antibody discovery using Phage Display Technology; and the supply of bespoke phage display libraries. In addition, IONTAS offers proprietary antibody discovery platforms including Mammalian Display where full length antibodies are expressed in the context of a mammalian cell thereby allowing selection based on function, stability, expression and developability; IONTAS have also developed a novel “KnotBody” format which facilitates the targeting of antibodies to ion channels, GPCRs and proteases.

About LG Chem, Ltd.

Having continued to grow over 7 decades since founded in 1947, LG Chem is leading the chemical industry in Korea.

The company has built the global network for production, sales and R&D not only in Korea but also in main bases across the world and has provided globally competitive products including ABS, polarisers and EV battery cells, raising its global position as a material supplier.

The company has strengthened market dominance starting from the Basic Materials & Chemicals business to Energy Solution, IT and Electronic Materials and has expanded its business into Life Science area, building a future-oriented business portfolio. In the long term, the company will build the foundation for sustainable growth by selecting and concentrating on the ‘energy’, ‘water’ and ‘bio’ businesses as the new growth engines.

LG Chem is committed to becoming a global company that realises the vision of “growing with customers by providing innovative materials and solutions” and provides new values to customers.

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for FairJourney Biologics (FJB) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner German Biotech Days 2024 in Berlin 650x300px

» top